MDGL - Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

2024-03-20 20:11:22 ET

Summary

• Interim results from the phase 2b/3 NAVIGATE study, using Belapectin for the prevention of esophageal varices in NASH Cirrhosis patients, expected Q4 of 2024.
• In a prior phase 2 study, it was shown that Belapectin was effective in treating patients who had not yet developed esophageal varices.
• Global non-alcoholic steatohepatitis market is expected to grow to $14.53 billion by 2028; 20% will develop NASH Cirrhosis and then about half will not have esophageal varices.
• Another advancement in the pipeline is the use of Belapectin in combination with Keytruda for the treatment of advanced head and neck squamous cell carcinoma.

Galectin Therapeutics ( GALT ) has a major milestone approaching towards the end of 2024, which is going to be the release of data from the phase 2b NAVIGATE study. This particular study is exploring the use of Belapectin for the prevention of esophageal varices in patients with NASH cirrhosis. I believe that investors should focus on this biotech, because it is gearing up to report topline results from the phase 2b/3 NAVIGATE study in Q4 of 2024. This is going to be an interim analysis, which if successful, will inform the company of whether or not it can accomplish two additional catalysts. The first of which would be the potential to file for regulatory approval of Belapectin to treat this patient population....

For further details see: